Latest news with #Gradient
Zawya
10-07-2025
- Business
- Zawya
South Africa: Cerebrium raises $8.5mln led by gradient to scale the leading high-performance serverless AI platform
Cerebrium, a serverless AI infrastructure platform founded in Cape Town, has successfully raised $8.5 million in seed funding, led by Gradient, Google's AI venture fund. The round also saw participation from Y Combinator, Authentic Ventures, and several strategic angel investors and operators. This funding milestone marks a significant achievement for South African tech, with local founders securing backing from one of the most influential AI investors in the world. The company and its innovative AI platform are at the forefront of technical advancements that enable teams to develop and scale multimodal AI applications without the traditional complexity or costs typically associated with such efforts. Founded in Cape Town and now headquartered in New York City, Cerebrium plans to use this new funding to invest in new features and meet the increasing enterprise demand. Cerebrium was founded by Michael Louis and Jonathan Irwin, former CTO and Lead Engineer at OneCart, respectively. OneCart, a South African tech company, was acquired by MassMart in 2021, marking one of the largest tech acquisitions in South Africa at the time. After experiencing firsthand the challenges of building AI-driven products, Louis and Irwin launched Cerebrium. CEO and Co-Founder, Michael Louis, comments: 'Tooling was fragmented, there was an education gap between theory and production, the unit economics didn't make sense, and development cycles took months. We built Cerebrium so engineers can focus on building AI products that users love with real business impact, instead of hiring an infrastructure team, racking up six-figure cloud bills or worrying about security and compliance.' Cerebrium powers some of the most innovative companies pushing the boundaries in AI, including Tavus, Deepgram, Vapi, and many more. The platform is built for high-performance, real-time multimodal AI applications such as voice agents, LLM fine-tuning, video models, and large-scale data analytics. 'We know that AI is changing the world, and we want Cerebrium, a South African founded company, to be the platform powering it,' concludes Louis. Several industry stakeholders have spoken highly of Cerebrium's progress. Roey Paz-Priel, Machine Learning Engineer at Tavus, shares: 'We run a range of real-time audio and video models, and performance is everything. We tried a number of solutions, but Cerebrium consistently delivered the speed and reliability we needed without the overhead. Even as we've scaled rapidly and gone viral, they've kept up with our compute demands and delivered the stability we rely on. It has become a core part of our infrastructure.' Eylul Kayin, Partner at Gradient, echoes this sentiment: 'What the Cerebrium team has pulled off with such a small group is incredible. They're powering some of the most advanced AI voice and video applications at scale and we believe specialized infrastructure which scales elastically will be essential as real-time AI becomes core to customer experiences.' While Cerebrium is renowned for its serverless GPU infrastructure, it also offers capabilities for batching, multi-region deployments, large-scale data processing, and much more. This allows teams to run compute-intensive workloads with minimal setup, scale elastically, and only pay for what they use—all while maintaining strict security and data residency requirements.
IOL News
08-07-2025
- Business
- IOL News
South African AI startup Cerebrium raises R150 million to scale its innovative platform
Cerebrium, a serverless AI infrastructure platform founded in Cape Town, has announced a successful $8.5 million (R151.35m) seed funding round, led by Gradient, Google's AI venture fund, with participation from Y Combinator, Authentic Ventures, and several strategic angel investors and operators. 'It's a remarkable milestone for South African tech, as local founders secure backing from one of the most influential AI investors in the world,' a statement from Cerebrium said Tuesday. The company and its AI platform have pioneered technical advancements that enable teams to build and scale multimodal AI applications without the traditional complexity or cost. Founded in Cape Town and now headquartered in New York City, this new funding will allow the team at Cerebrium to invest in new features and meet surging enterprise demand.
Yahoo
18-06-2025
- Business
- Yahoo
Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company's recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System. The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations. The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. 'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.' About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use. For more information, please visit: CONTACT: Media Contact contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-06-2025
- Business
- Yahoo
Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug Administration (FDA) for the development of its novel technology intended to treat patients with pulmonary hypertension and associated heart failure. The TAP Pilot acceptance follows the Company's recent announcement that the FDA granted Breakthrough Device Designation for the Gradient Denervation System. The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations. The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures. 'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.' About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use. For more information, please visit: CONTACT: Media Contact contact@
Yahoo
09-06-2025
- Business
- Yahoo
Gradient Mortgage Capital Launches to Empower Mortgage Professionals with Premier Small Balance Commercial and DSCR Mortgage Lending Solutions
An Affiliate of Saluda Grade, Gradient Offers Tailored Wholesale Loan Solutions for 1–4-Unit Investor Residential and Small Balance Commercial Properties FORT LAUDERDALE, Fla., June 9, 2025 /PRNewswire/ -- Gradient Mortgage Capital, a newly launched wholesale mortgage banking platform, is excited to announce its official market entry, offering innovative financing solutions to mortgage bankers and brokers nationwide. Specializing in Debt Service Coverage Ratio (DSCR) loans for 1-4-unit investor residential properties and Small Balance Commercial Real Estate (SBCRE) loans for a wide variety of property types, Gradient is committed to providing fast, flexible, and reliable lending solutions that help clients scale with confidence. As an affiliate of Saluda Grade, an alternative investment firm specializing in asset-based credit, Gradient benefits from the backing of a firm focused on emerging asset classes and innovative capital solutions. This affiliation provides Gradient with the financial resources to offer mortgage bankers and brokers a competitive edge in a rapidly evolving marketplace. Gradient Mortgage Capital understands that every deal is unique, which is why their loan solutions are designed to help mortgage intermediaries assist entrepreneurial real estate investors at every stage of their journey. Whether their borrower is acquiring their first investment property or refinancing an expanding portfolio, Gradient's streamlined process and commonsense underwriting provide speed and certainty of close, ensuring borrowers get the financing they need when they need it most. "Our mission is rooted in delivering exceptional value through creativity, consistency, and commitment," said Jeremy Irwin, CEO of Gradient Mortgage Capital. "We're here to support our partners with a deep focus on the customer experience, earning your trust by making every interaction reliable, transparent, and frictionless. With Gradient, it's not just about funding transactions; it's about building lasting relationships and helping our partners grow." By combining capital, creativity, and consistency, Gradient offers more than just loans—it builds momentum. With a focus on collaboration, exceptional service, and a commitment to getting deals done right, Gradient provides mortgage professionals with the tools they need to succeed in a competitive landscape. Gradient Mortgage Capital's tagline, "Where Opportunity Meets Altitude," reflects the company's vision to elevate its clients by delivering tailored lending solutions that empower growth, drive success, and unlock new opportunities. For more information about Gradient Mortgage Capital, its DSCR and Small Balance Commercial loan programs, or to become an approved partner, visit About Gradient Mortgage CapitalGradient Mortgage Capital is a wholesale mortgage banking platform and affiliate of Saluda Grade, specializing in DSCR loans for 1–4-unit investor residential properties and Small Balance Commercial Real Estate (SBCRE) loans. With a focus on speed, flexibility, and exceptional service, Gradient empowers mortgage brokers and bankers to deliver tailored financing solutions that help real estate investors scale smarter and more efficiently. About Saluda GradeSaluda Grade is an alternative investment firm specializing in asset-based finance, with a focus on residential real estate. Founded in 2019, the firm has an AUM of $2.5 billion* as of June 1, 2025, and is headquartered in New York City. Disclaimer: This press release is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any securities or investment products. All investing involves risk, including the potential loss of principal.* Saluda Grade acquired Hillcrest Finance, LLC on June 1, 2025. Integration of business operations is ongoing; at this time, the regulatory assets under management (AUM) of the two entities remains as an investment adviser does not imply a certain level of skill or training. View original content to download multimedia: SOURCE Gradient Mortgage Capital, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
